AGL 38.20 Increased By ▲ 0.05 (0.13%)
AIRLINK 129.30 Increased By ▲ 4.23 (3.38%)
BOP 7.85 Increased By ▲ 1.00 (14.6%)
CNERGY 4.66 Increased By ▲ 0.21 (4.72%)
DCL 8.35 Increased By ▲ 0.44 (5.56%)
DFML 38.86 Increased By ▲ 1.52 (4.07%)
DGKC 82.20 Increased By ▲ 4.43 (5.7%)
FCCL 33.64 Increased By ▲ 3.06 (10.01%)
FFBL 75.75 Increased By ▲ 6.89 (10.01%)
FFL 12.83 Increased By ▲ 0.97 (8.18%)
HUBC 110.72 Increased By ▲ 6.22 (5.95%)
HUMNL 14.03 Increased By ▲ 0.54 (4%)
KEL 5.22 Increased By ▲ 0.57 (12.26%)
KOSM 7.69 Increased By ▲ 0.52 (7.25%)
MLCF 40.08 Increased By ▲ 3.64 (9.99%)
NBP 72.51 Increased By ▲ 6.59 (10%)
OGDC 189.18 Increased By ▲ 9.65 (5.38%)
PAEL 25.74 Increased By ▲ 1.31 (5.36%)
PIBTL 7.38 Increased By ▲ 0.23 (3.22%)
PPL 153.45 Increased By ▲ 9.75 (6.78%)
PRL 25.52 Increased By ▲ 1.20 (4.93%)
PTC 17.92 Increased By ▲ 1.52 (9.27%)
SEARL 82.50 Increased By ▲ 3.93 (5%)
TELE 7.63 Increased By ▲ 0.41 (5.68%)
TOMCL 32.50 Increased By ▲ 0.53 (1.66%)
TPLP 8.48 Increased By ▲ 0.35 (4.31%)
TREET 16.74 Increased By ▲ 0.61 (3.78%)
TRG 56.01 Increased By ▲ 1.35 (2.47%)
UNITY 28.85 Increased By ▲ 1.35 (4.91%)
WTL 1.34 Increased By ▲ 0.05 (3.88%)
BR100 10,659 Increased By 569.2 (5.64%)
BR30 31,331 Increased By 1822.5 (6.18%)
KSE100 99,269 Increased By 4695.1 (4.96%)
KSE30 31,032 Increased By 1587.6 (5.39%)

Britain's leading shares rose on Monday, boosted by gains in retailer Marks & Spencer as hopes for a bid spurred on its recovery following last week's dismal trading statement.
Among mid-caps, bookseller WH Smith raced up 34 percent to 349-1/2 pence after it said UK private equity firm Permira had approached it about a bid at a possible price of 375 pence a share, valuing the company at around 940 million pounds ($1.7 billion).
The FTSE-100 index put on a late show of strength to close up 8.9 points, or 0.2 percent, at 4,546.2, rising for the third session in a row. The index, which ended at its best level in five weeks, has risen 3.7 percent so far this month.
But weaker oil firms BP and Shell held the market back after Opec said it would continue to supply red-hot oil markets with excess crude above official group limits to cool oil prices.
Both BP and Shell shed around one percent. Earlier Shell announced the departure of Chief Financial Officer Judy Boynton, the latest casualty of the fall-out from surprise cuts to its oil and gas reserves that angered investors.
Peter Bodycombe, a fund manager at Singer & Friedlander Investment Management said the FTSE may still be capped by concerns over the direction of US markets.
"A lot of it depends on how confident we feel about the United States moving forward, because it's so much the dominant player," he said. "And deep at the back of everyone's minds is the unquantifiable impact of what happens in the Middle East."
Turnover was a sluggish two billion shares, reflecting caution ahead of Wednesday's Congressional testimony from Federal Reserve Chairman Alan Greenspan.
Investors are anxious for clues as to the timing of any rate rise.
Marks & Spencer led blue chip gainers with a rise of just under five percent after a report in newspaper The Business that US buy-out specialists and UK retail entrepreneur Philip Green were among those eyeing the department store chain offset disappointment over last week's disastrous trading update.
"It is not our belief that Marks & Spencer is in terminal decline and therefore we would see any bid as opportunistic and, in our view, at completely the wrong time for shareholders to sell out," said Richard Ratner, an analyst at brokerage Seymour Pierce.
Elsewhere among blue chip retailers, supermarket chain Tesco rose 3.3 percent. Dealers said hopes for robust earnings on Tuesday had sparked interest in the stock.
Among mid-caps, hopes for a round of consolidation in the sector lifted high-street names Woolworths, Somerfield and Matalan.
But Big Food Group slipped 6.3 percent, dented by a report in the Financial Mail on Sunday that sales at its Iceland frozen food chain had fallen over the Easter break.
Back among blue chips, drug-maker AstraZeneca dipped 1.4 percent after the Anglo-Swedish company sent a letter to doctors in Canada warning of potential liver problems associated with asthma drug Accolate.
The fall compounded a drop on Friday triggered by news that an Indian firm had given notice that it was looking to produce a cheap generic version of AstraZeneca's $1.5 billion-a-year schizophrenia drug Seroquel.

Copyright Reuters, 2004

Comments

Comments are closed.